Tagged with MEA

MEA Rare diseases in the Middle East and Africa are no longer an afterthought. As regulatory frameworks mature and governments demand deeper partnership, access, science and local commitment are being redefined. In this interview, Sherif Basha explains how Versalya Pharma is building a rare diseases platform designed for long-term impact, translating…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

MEA Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward Saudi biotechs, Egypt’s collaboration with Turkey on pharma manufacturing, and China’s ‘health silk road’ in Africa.   Saudi Arabia pitches…

Switzerland Chantal Friebertshäuser, SVP Europe & Middle East, is spearheading Moderna’s ambitious expansion beyond COVID-19 vaccines, leveraging mRNA technology to target cancers and latent viruses across diverse markets. She champions a hyper-localised strategy to navigate Europe and the Middle East’s complex healthcare landscapes. Her vision positions Moderna not as a pandemic…

MEA The Middle East and Africa (MEA) pharmaceutical market is booming. According to IQVIA, the market reached USD 32.6 billion in value last year with value sales growth at 10.5 percent versus the previous year. Saudi Arabia, the largest market in MEA at USD 11.6 billion in value, expanded at 9.1…

Africa Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold, a consultant to the Gates Foundation, unveil the “Continental List of Human Medicinal Products” pilot—a first-of-its-kind initiative led by the…

LatAm Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD 560 million; a worrying new report from the Pan-American Health Organisation showing that measles cases are up 29-fold in the…

MEA A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines; Jordan’s Hikma makes a USD 1 billion investment pledge for US manufacturing and R&D, and Riyadh-headquartered private equity firm Jadwa…

Saudi Arabia Localising the production of medicines has become a core priority for the Saudi government over the past decade as it attempts to increase national health security, create highly skilled jobs, and grow the non-oil economy. Multinational innovators now have a wide range of incentives (as well as enforcement tactics) to…

Saudi Arabia With Saudi Arabia striving to position itself as a regional leader in biopharmaceutical R&D by 2030 and to cement itself as a global hub before 2040, there has been a coordinated attempt to align research centres across the country under a unified national framework. This National Biotech Strategy, unveiled by…

Saudi Arabia Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North Africa region, but its medical device sector has been experiencing consistent compound annual growth rates of over six percent and…

Saudi Arabia Eye health is vital to everyday life, yet it remains heavily underfunded compared to fields like cancer or diabetes. While global spending on oncology is set to reach USD 440 billion by 2028, ophthalmology will receive just USD 38 billion, according to IQVIA. This gap is striking given the growing…